Sectors

Norgine, Axa and Debiopharm are in line for exits as the breast cancer diagnostics test provider is aiming to go public to boost research and development and commercial activities.

Existing investor Lennar returned to back the modular homebuilder in a round led by Gigafund, bringing its overall funding to over $71m.

SoftBank’s Vision Fund 2 led a $59.7m round which will support Aculys in bringing a sleep disorder medication it has licensed to Japan.

Cell therapy developer Hopstem completed a $40m Eli Lilly-backed series B round while cybersecurity technology developer SlashNext secured $26m from investors including Telia and Ayala Group.

Yingtong Technology and LY.com were among the backers in a $1.2bn round for the Changan, FAW, Dongfeng Motor, Tencent, Alibaba and Suning-founded on-demand ride provider.

The Info Edge, Intel, Tencent and SoftBank-backed operator of insurance and financial products comparison tools PolicyBazaar and PaisaBazaar has gone public, having raised $343m in pre-IPO funding.

The Prosus and Benesse-backed online skills learning marketplace priced its shares at the top of their range to raise approximately $421m.

The Merck & Co and Roche-backed Duchenne muscular dystrophy drug developer has gone public in an upsized IPO sized at approximately $182m.

China Telecom was among the participants in a round for the smart home device maker which will support international growth and research and development.

Henry Crown and Company achieved an exit as the root canal technology developer listed on the New York Stock Exchange below its IPO range.

Chiesi, Lundbeck and Li-Cor Biosciences scored exits as the oncology therapy developer floated in an upsized $75.6m initial public offering.